Tacrolimus (all routes)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Wielgos, 2012 Perales-Puchalt, 2012 20.46[0.07; 3.05]430not evaluable Major congenital malformations Wielgos, 2012 10.37[0.04; 3.14]421not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Perales-Puchalt, 2012 Kim, 2015 Ichinose, 2018 Al-Otaibi, 2019 40.99[0.36; 2.69]5082not evaluable Low birth weight (< 2500g) Kim, 2015 Ichinose, 2018 22.02[0.86; 4.75]2743not evaluable Small for gestational age (weight) Thompson, 2003 Perales-Puchalt, 2012 20.87[0.12; 6.18]1213not evaluable Maternal consequences Preeclampsia Thompson, 2003 Perales-Puchalt, 2012 Wielgos, 2012 Alvaro, 2013 42.26[0.63; 8.11]1949not evaluable Caesarean Perales-Puchalt, 2012 Kim, 2015 Al-Otaibi, 2019 31.34[0.73; 2.48]9270not evaluable Gestational diabete Wielgos, 2012 11.31[0.05; 35.47]121not evaluable Maternal consequences (as a whole) Sugawara, 2019 11.18[0.36; 3.87]3416not evaluable Neonatal disorders Fetal distress Ichinose, 2018 10.48[0.04; 5.18]-15not evaluable Intrauterine deaths Early intrauterine death (< 22 weeks) Al-Otaibi, 2019 17.95[0.37; 171.28]233not evaluable Late intrauterine deaths (> 22 weeks) Perales-Puchalt, 2012 Al-Otaibi, 2019 20.95[0.04; 20.57]342not evaluable0.0100.01.0